Viamet Pharmaceuticals, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Viamet Pharmaceuticals, Inc. – Product Pipeline Review – 2016’, provides an overview of the Viamet Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Viamet Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Viamet Pharmaceuticals, Inc.

The report provides overview of Viamet Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Viamet Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Viamet Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Viamet Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Viamet Pharmaceuticals, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Viamet Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Viamet Pharmaceuticals, Inc. Snapshot 5

Viamet Pharmaceuticals, Inc. Overview 5

Key Information 5

Key Facts 5

Viamet Pharmaceuticals, Inc. - Research and Development Overview 6

Key Therapeutic Areas 6

Viamet Pharmaceuticals, Inc. - Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products - Monotherapy 9

Viamet Pharmaceuticals, Inc. - Pipeline Products Glance 10

Viamet Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 10

Phase II Products/Combination Treatment Modalities 10

Phase I Products/Combination Treatment Modalities 11

Viamet Pharmaceuticals, Inc. - Early Stage Pipeline Products 12

Preclinical Products/Combination Treatment Modalities 12

Viamet Pharmaceuticals, Inc. - Drug Profiles 13

VT-1161 13

Product Description 13

Mechanism of Action 13

R&D Progress 13

VT-1129 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

Small Molecules for Oncology 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

Small Molecules for Orphan Diseases 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

VT-1598 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

VT-1607 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

VT-1654 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

VT-1658 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

VT-1669 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

VT-1681 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Viamet Pharmaceuticals, Inc. - Pipeline Analysis 24

Viamet Pharmaceuticals, Inc. - Pipeline Products by Target 24

Viamet Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 25

Viamet Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 26

Viamet Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 27

Viamet Pharmaceuticals, Inc. - Recent Pipeline Updates 28

Viamet Pharmaceuticals, Inc. - Locations And Subsidiaries 31

Head Office 31

Appendix 32

Methodology 32

Coverage 32

Secondary Research 32

Primary Research 32

Expert Panel Validation 32

Contact Us 32

Disclaimer 33

List of Tables

List of Tables

Viamet Pharmaceuticals, Inc., Key Information 5

Viamet Pharmaceuticals, Inc., Key Facts 5

Viamet Pharmaceuticals, Inc. – Pipeline by Indication, 2016 7

Viamet Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2016 8

Viamet Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2016 9

Viamet Pharmaceuticals, Inc. – Phase II, 2016 10

Viamet Pharmaceuticals, Inc. – Phase I, 2016 11

Viamet Pharmaceuticals, Inc. – Preclinical, 2016 12

Viamet Pharmaceuticals, Inc. – Pipeline by Target, 2016 24

Viamet Pharmaceuticals, Inc. – Pipeline by Route of Administration, 2016 25

Viamet Pharmaceuticals, Inc. – Pipeline by Molecule Type, 2016 26

Viamet Pharmaceuticals, Inc. – Pipeline Products by Mechanism of Action, 2016 27

Viamet Pharmaceuticals, Inc. – Recent Pipeline Updates, 2016 28

List of Figures

List of Figures

Viamet Pharmaceuticals, Inc. – Pipeline by Indication, 2016 7

Viamet Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2016 8

Viamet Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2016 9

Viamet Pharmaceuticals, Inc. – Pipeline by Target, 2016 24

Viamet Pharmaceuticals, Inc. – Pipeline by Route of Administration, 2016 25

Viamet Pharmaceuticals, Inc. – Pipeline by Molecule Type, 2016 26

Viamet Pharmaceuticals, Inc. – Pipeline Products by Mechanism of Action, 2016 27

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports